Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ridgeback Biotherapeutics LP

https://www.ridgebackbio.com/

Latest From Ridgeback Biotherapeutics LP

Japan Makes Renewed Policy Efforts To Fill 'Drug Gap'

Japan has announced several new measures to tackle the lack of rare disease and other therapeutics in the domestic market, with the country's main industry association also issuing the first common national informed consent form in a bid to lighten the “huge workload” on trial site staff.

Japan Drug Review

Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA

The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.

Coronavirus COVID-19 Infectious Diseases

AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market

AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.

Europe Approvals

EU Crunch Time For Previously Rejected Lagevrio & Other New Drugs

MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.

Europe Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
UsernamePublicRestriction

Register